When your doctor talks about a new medicine for your arthritis, diabetes, or cancer, you might hear the word biosimilar. It sounds technical, maybe even scary. But here’s the truth: biosimilars aren’t experimental or second-rate. They’re carefully made, FDA-approved copies of powerful biologic drugs - and they can save you money without sacrificing safety or effectiveness.
What’s the difference between a biosimilar and a regular generic drug?
Most people know what generics are. If you’ve taken a cheap version of ibuprofen or metformin, you’ve used a generic. These are exact chemical copies of small-molecule drugs. They’re simple to make because the molecule is tiny and stable. Biosimilars are nothing like that. Biologic drugs - the ones biosimilars copy - are made from living cells. Think of them like a complex protein recipe using human or animal cells as tiny factories. These proteins can be huge, with twists, folds, and sugar attachments that change how they work. Even tiny changes in how they’re made - the type of cell used, the temperature during production, how they’re purified - can affect the final product. Because of this, a biosimilar can’t be an exact copy. It’s not like swapping one brand of aspirin for another. Instead, it’s like building a new car that looks, drives, and performs almost identically to a luxury model - down to the engine sound and how it handles bumps. The FDA requires proof that any differences between the biosimilar and the original are so small they don’t affect safety or how well it works.How do we know biosimilars are safe?
You might worry: if it’s not identical, how can it be safe? The answer is science - and a lot of it. Before a biosimilar gets approved, it goes through more than 100 tests. Scientists compare it to the original biologic at the molecular level. They check its shape, its charge, how it binds to targets in the body, and how stable it is. Then they test it in animals. Finally, they run clinical trials in people - often hundreds of them - to make sure it works the same way, causes the same side effects, and doesn’t trigger unexpected reactions. For example, the biosimilar Renflexis, used for rheumatoid arthritis, was tested in 541 patients before approval. The results? No meaningful difference in how well it worked or how safe it was compared to the original drug, Remicade. In Europe, biosimilars have been used for over 15 years. Millions of patients have taken them. No new safety problems have appeared. The FDA, the European Medicines Agency, and major cancer and arthritis groups all agree: approved biosimilars are as safe and effective as the originals.What conditions are biosimilars used for?
Biosimilars aren’t just for one disease. They’re used to treat serious, long-term conditions where biologics have changed the game:- Autoimmune diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis (using drugs like adalimumab and infliximab)
- Certain cancers, including breast cancer and colorectal cancer (using trastuzumab and bevacizumab)
- Diabetes (insulin glargine biosimilars)
- Chronic kidney disease and anemia (epoetin alfa biosimilars)
- Eye diseases like macular degeneration (ranibizumab biosimilars)
Will my insurance cover a biosimilar?
Often, yes - and sometimes, they’ll make you try it first. Many insurance plans now push for biosimilars because they’re cheaper. Your doctor might get a letter from your insurer saying, “We’ll cover the biosimilar, but not the brand-name version unless you’ve tried the biosimilar first.” This is called step therapy, and it’s legal and common. But here’s the good news: if your doctor believes the original biologic is better for you - maybe because you’ve had side effects or it’s working perfectly - they can appeal. You’re not forced to switch if it’s not right for you.
What’s with the weird drug names?
You’ll notice biosimilars have long, strange names. That’s not a mistake. The FDA requires all biosimilars to have a four-letter suffix added to the generic name. For example:- Original: infliximab
- Biosimilar: infliximab-dyyb (Renflexis)
- Another biosimilar: infliximab-abda (Renflexis)
Can I switch from the original to a biosimilar?
Yes - and studies show it’s safe. A lot of patients worry about switching. What if my body reacts differently? What if my disease flares up? Multiple studies - including ones from the Arthritis Foundation and the American Cancer Society - show that switching from a brand-name biologic to a biosimilar doesn’t increase side effects or reduce effectiveness. Patients who switched kept doing well. Their symptoms stayed under control. Their blood tests stayed normal. Some patients even switch back and forth without issue. The FDA has approved certain biosimilars as “interchangeable.” That means a pharmacist can swap them for the original without asking your doctor - just like generics. The first interchangeable biosimilar was Semglee, an insulin glargine, approved in 2021.Why aren’t biosimilars cheaper like generics?
Good question. Generics cost 80-90% less because making a chemical pill is simple. Biosimilars cost 15-30% less because making a living-cell drug is like cloning a complex machine - not just copying a blueprint. The factories, the testing, the quality controls are expensive. Still, even a 20% savings on a $40,000 drug means $8,000 saved per year. Multiply that by thousands of patients, and you’re talking about billions saved for the healthcare system.
What should I do if my doctor suggests a biosimilar?
Ask questions. But don’t assume it’s a downgrade. Here are three simple things to ask:- Is this biosimilar approved by the FDA for my condition?
- Has it been tested in people like me?
- Will my insurance cover it, and if not, what are my options?
What’s next for biosimilars?
The market is growing fast. In the U.S., only about 10% of biologic prescriptions are for biosimilars. In Europe, it’s 25%. That gap is shrinking. More biosimilars are coming - for popular drugs like Humira and Enbrel. The FDA is making the approval process faster. And as more companies enter the market, prices will drop even further. The goal? More patients getting the medicines they need - without being priced out.Final thought: Biosimilars aren’t a compromise. They’re progress.
They’re not the same as generics. They’re not cheaper because they’re weaker. They’re the result of decades of scientific progress - a way to bring life-changing treatments to more people. If your doctor suggests a biosimilar, it’s not because they’re running out of options. It’s because they’ve looked at the science - and they know you can get the same results, safely, at a lower cost. Talk to them. Ask questions. But don’t let a complicated name scare you off. Your health matters - and so does your wallet.Are biosimilars the same as generics?
No. Generics are exact chemical copies of small-molecule drugs like aspirin or metformin. Biosimilars are highly similar - but not identical - copies of complex biologic drugs made from living cells. Because biologics are made by living systems, exact copies aren’t possible. Biosimilars must prove they work the same way and are just as safe, but they’re not chemically identical.
Can I switch from my brand-name biologic to a biosimilar safely?
Yes. Multiple studies show that switching from a brand-name biologic to a biosimilar doesn’t increase side effects or reduce effectiveness. Patients with arthritis, cancer, and other conditions have switched and maintained the same level of control over their disease. The FDA has even approved some biosimilars as "interchangeable," meaning a pharmacist can swap them without asking your doctor.
Why do biosimilars have strange names with four-letter endings?
The FDA requires a unique four-letter suffix to tell biosimilars apart from the original drug and from each other. This helps doctors and pharmacists track which version a patient took if there’s a side effect or reaction. For example, the biosimilar version of infliximab is called infliximab-dyyb. It’s not meant to confuse you - it’s for your safety.
Are biosimilars covered by insurance?
Often yes - and sometimes your plan will require you to try a biosimilar first before covering the brand-name drug. This is called step therapy. But if your doctor believes the original is better for you, they can file an appeal. Insurance companies accept these appeals frequently when there’s medical justification.
How much cheaper are biosimilars than the original biologics?
Biosimilars typically cost 15% to 30% less than the original biologic. While that’s not as big a discount as generics (which can be 80-90% cheaper), it still saves patients thousands per year. For drugs that cost $40,000 or more annually, even a 20% reduction means real financial relief.
Do biosimilars have the same side effects as the original?
Yes. Before approval, biosimilars must show they have the same potential side effects as the original biologic. Clinical trials compare not just effectiveness, but also safety profiles. If the original drug causes fatigue or increased infection risk, the biosimilar must show the same pattern. No new or unexpected side effects have been found in approved biosimilars.
Are biosimilars used outside the U.S.?
Yes. Biosimilars have been used safely in Europe for over 15 years, with millions of patients taking them. Countries like Germany, the UK, and Sweden have high adoption rates. The European Medicines Agency has the same strict standards as the FDA. Real-world data from Europe confirms that biosimilars perform just as well as the originals over the long term.
Write a comment